CURE Pharmaceutical to Participate in Panel Discussion on the Future of Clinical Research using Cannabis at The Cannabis Science Conference in Portland, OR OXNARD, Calif., Aug. 29, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...

CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis OXNARD, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, today announced that its subsidiary company, Oak...

CURE Pharmaceutical Expects Increased Demand for Its Enhanced Transdermal Drug Delivery Platform OXNARD, Calif., July 05, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...

Leading OTF Manufacturer CURE Pharmaceutical Comments on New Report Showing Exponential Growth in Thin Film Drug Manufacturing Market OXNARD, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...